Prevea Neurosurgeon First in State to Use New Tool

Dr. Joseph Chabot. Submitted.

About 17,000 new cases of high-grade gliomas are expected to be diagnosed nationally in 2019, according to the Central Brain Tumor Registry of the United States. Gliomas account for 80 percent of all malignant brain tumors.

This month, Dr. Joseph Chabot, a Prevea Health neurosurgeon, became the first in Wisconsin to use Gleolan: a new breakthrough tool designed to make the surgical removal of high-grade gliomas more effective. Gleolan is an imaging agent (or dye) that shows the surgeon where the cancerous tissue is located within the brain. Chabot is specially trained in removing complex brain tumors, and he’s the only neurosurgeon in northeast Wisconsin with fellowship training in open and endoscopic skull-base surgery. He also participated in the clinical trial that led to FDA approval of Gleolan in the U.S. in 2017.